title: Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder.
abstract: There are no reports of a child taking a selective serotonin reuptake inhibitor and an atypical anti-psychotic being successfully tapered from these medications after completion of cognitive-behavioral therapy (CBT) for obsessive-compulsive disorder. With this in mind, we report the case of an 8.5-year-old male who was taking risperidone 0.5 mg bid, sertraline 100 mg, and atomoxetine 25 mg at presentation. After a successful course of CBT, we describe how medications were systematically withdrawn. Implications of this case on practice parameters (e.g., CBT may be an effective augmenting agent for those non-responsive to initial pharmacological treatments) are highlighted.
authors.forename: Robert B
authors.initials: RB
authors.lastname: Goldstein
authors.forename: Eric A
authors.initials: EA
authors.lastname: Storch
authors.forename: Heather
authors.initials: H
authors.lastname: Lehmkuhl
authors.forename: Gary R
authors.initials: GR
authors.lastname: Geffken
authors.forename: Wayne K
authors.initials: WK
authors.lastname: Goodman
authors.forename: Tanya K
authors.initials: TK
authors.lastname: Murphy
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000628:therapy; D002648:Child; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D003131:Combined Modality Therapy; D015897:Comorbidity; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000628:therapy*; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects*; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D020280:Sertraline / Q000008:administration & dosage / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000517:prevention & control*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D014150:Antipsychotic Agents; D000069445:Atomoxetine Hydrochloride; D011437:Propylamines; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline